Abstract
W hen scientists isolated strains of methicillin-resistant Staphylococcus aureus (MRSA) that also showed intermediate resistance to vancomycin - the current treatment of last resort - headlines in the UK and elsewhere prophesied the end of the antibacterial miracle. Certainly, MRSA poses a serious clinical and economic problem, delegates to the International Congress of Chemotherapy [ Birmingham, UK; July, 1999 ] recently heard. But reports of the demise of the antibacterial miracle may have been exaggerated.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Greener, M. MRSA. Pharmacoecon. Outcomes News 225, 3–4 (1999). https://doi.org/10.1007/BF03275016
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03275016